(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 January 2011 (27.01.2011)

PCT

(10) International Publication Number
WO 2011/009623 A1

(51) International Patent Classification:
C07K 16/00 (2006.01) *C07K 16/32* (2006.01)
C07K 1/14 (2006.01)

(21) International Application Number:
PCT/EP2010/004509

(22) International Filing Date:
22 July 2010 (22.07.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09009640.5 24 July 2009 (24.07.2009) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BURG, Josef** [DE/DE]; Merowingerstrasse 5, 82362 Weilheim (DE). **HILGER, Bernhard** [DE/DE]; Am Katzenbuckel 21, 82377 Penzberg (DE). **KAISER, Thorsten** [DE/DE]; Rosenweg 14, 82387 Antdorf (DE). **KUHNE, Wolfgang** [DE/DE]; Wolfbauerweg 10, 82377 Penzberg (DE). **STIENS, Lars** [DE/DE]; Kormannstrasse 14, 82362 Weilheim (DE). **WALLERIUS, Claus** [DE/DE]; Mitterweg 4, 82404 Sindelsdorf (DE). **ZETTL, Frank** [DE/DE]; Wettersteinstrasse 8, 82061 Neuried (DE).

(74) Agent: **BURGER, Alexander**; Roche Diagnostics GmbH, Patent Department (TR-E), Postfach 11 52, 82372 Penzberg (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

[Continued on next page]

(54) Title: OPTIMIZING THE PRODUCTION OF ANTIBODIES

Fig. 1



(57) Abstract: A general method is provided for the production of purified antibodies by separation of an antibody molecule from an antibody variant by chromatographic methods, e.g. to enhance therapeutic efficacy, by for example choosing a specific harvesting time point and/or a specific purification scheme. The current invention thus reports a method for producing an antibody composition comprising an antibody molecule and a variant thereof, comprising the following steps: providing a sample comprising the antibody molecule and a variant thereof, determining the presence of the antibody molecule and/or a variant thereof and/or the ratio of the amount of the antibody molecule or variant thereof to the sum of the amounts of the antibody molecule and the variant thereof, in an aliquot of said sample, determining a subsequent harvesting time point and/or antibody purification scheme on basis of the data obtained before, thereby producing an antibody composition comprising the antibody molecule and a variant thereof.

WO 2011/009623 A1

Published:

— *with international search report (Art. 21(3))*